Literatur
- 1
Als-Nielsen B, Chen W, Gluud C. et al .
Association of funding and conclusions in randomized drug trials.
JAMA.
2003;
290
921-928
- 2
Carpenter G.
Italian doctors faces charges over GSK incentive scheme.
Lancet.
2004;
363
1873
- 3
Chan A -W, Hrobjartsson A, Haahr M T. et al .
Empirical Evidence for selective reporting of outcomes in randomized trials. Comparison
of protocols to published articles.
JAMA.
2004;
291
2457-2465
- 4
Coyle S L. for the Ethics and Human Right Committee .
Physician-industry relations. Part 1: Individual physicians.
Ann Intern Med.
2002;
136
396-402
- 5
Coyle S L.
Physician-industry relations. Part 2: Organizational issues.
Ann Intern Med.
2002;
136
403-406
- 6
Creutzfeldt W.
Ärztliches Ethos im medizinisch-industriellen Komplex.
Med Klin.
1993;
88
658-664
- 7
Dana J, Loewenstein G.
A social science perspective on gifts to physicians from industry.
JAMA.
2003;
290
252-255
- 8
Davidoff F, De Angelis C D, Drazen J M. et al .
Sponsorship, authorship, and accountability.
Lancet.
2001;
358
854-856
- 9 Engelhardt K. Der medizinisch-industrielle Komplex. Agenda, Münster In: Kranke Medizin.
Das Abhandenkommen des Patienten 1999: 51-55
- 10
Engelhardt K.
Ethische Probleme der Placebobenutzung.
Dtsch Med Wochenschr.
2004;
129
1939-1942
- 11
Farmer J A.
Learning from the Cerivastatin experience.
Lancet.
2001;
358
1383-1385
- 12
Fletcher R H.
Adverts in medical journals: caveat lector (Commentary).
Lancet.
2003;
361
10-11
- 13
Josefson D.
Doctors warned to be wary of new drugs.
BMJ.
2002;
324
1113
- 14
Jüni P, Nartey L, Reichenbach S. et al .
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
Lancet.
2004;
364
2021-2029
- 15
Kessler D A.
Drug promotion and scientific exchange.
N Engl J Med.
1991;
325
201-203
- 16
Kjaergard L L, Als-Nielsen B.
Association between competing interests and authors conclusion: epidemiology study
of randomised clinical trials published in the BMJ.
BMJ.
2002;
325
249-252
- 17
Larkin M.
Whose article is it anyway?.
Lancet.
1999;
354
136
- 18
Lazarou J, Pomeranz B H, Corey P N.
Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective
studies.
JAMA.
1998;
279
1200-1205
- 19
Lexchin J, Bero L A, Djulbegovic B. et al .
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
BMJ.
2003;
326
1167-1170
- 20 Lüllmann H, Mohr K, Wehling M. Pharmakologie und Toxikologie. Arzneimittelwirkungen
verstehen - Medikamente gezielt einsetzen. 15. Aufl Thieme, Stuttgart 2003 VI
- 21
Maio G.
Zur Geschichte der Contergan-Katastrophe im Lichte der Arzneimittelgesetzgebung.
Dtsch Med Wochenschr.
2001;
126
1183-1186
- 22 Maio G. Das Menschenbild als Grundlage der medizinischen Ethik. Thieme, Stuttgart
In: Über das Menschenbild in der Medizin, hg. HE Blum u. R. Haas 2004: 41-47
- 23
Mc Carthy M.
Conflikt of interest highlighted in debate on calcium-channel blockers.
Lancet.
1998;
351
191
- 24
Meyboom R HB, Edwards I R.
Rosuvastatin and the statin wars - the way to peace.
Lancet.
2004;
364
1997-1999
- 25 Middeke M. Arterielle Hypertonie. Thieme, Stuttgart 2005: 150
- 26
Moynihan R.
Who pays for the pizza? Redefining the relationships between doctors and drug companies.
1. Entanglement.
BMJ.
2003;
326
1189-1192
- 27
Psaty B M, Furberg C D, Ray W A. et al .
Potential for conflict of interest in the evaluation of suspected adverse drug reactions.
Use of cerivastatin and risk of rhabdomyolysis.
JAMA.
2004;
292
2622-2631
- 28
Rundall P.
How much research in infant feeding comes from unethical marketing?.
BMJ.
1998;
317
338-339
- 29
Schrör K.
Kardiovaskuläre Risiken von COX-2-Hemmern.
Dtsch Med Wochenschr.
2004;
129
2653-2656
- 30
Schroter S, Morris J, Chaudhry S. et al .
Does the type of competing interest statement affect readers’ perceptions of the credibility
of research? Randomized trial.
BMJ.
2004;
328
742-743
- 31
Steinbrook R.
Commercial support and continuing medical education.
N Engl J Med.
2005;
352
534-535
- 32
Stelfox H T, Chua G, O’Rourke K. et al .
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med.
1998;
338
101-106
- 33
The Lancet .
How a statin might destroy a drug company.
Lancet.
2003;
361
793
- 34
Topol E J.
Arthritis medicines and cardiovascular events - „house of coxibs”.
JAMA.
2005;
293
366-368
- 35
Weatherall D J.
The doctor’s dilemma.
Lancet.
2005;
365
207-208
- 36
Weber W.
Sponsored continuing medical education under scrutiny in Europe.
Lancet.
2001;
357
452
Professor Dr. med. Karlheinz Engelhardt
Jaegerallee 7
24159 Kiel
